Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Nov 28, 2019 10:44pm
146 Views
Post# 30404398

RE:Theralase Cannabinoid/PDC/Radiation Patent

RE:Theralase Cannabinoid/PDC/Radiation PatentEoganacht ... Great digging.  Thanks for the update.  Cannabioid is still in the plan.  That's interesting.

They won't move on the GBM indication though until they get the patent protection on all of the pieces of this treatment.

On some of our other patents, I wonder how much time we usually had between this status:

... 2019-11-28 Application status is Pending

and the "granted" one.

That could help us assess how much time we would have to wait on that one.

________________________

Eoganacht - (11/28/2019 5:49:20 PM)
Theralase Cannabinoid/PDC/Radiation Patent
Google Patents 20190290657

Method for treating conditions associated with hyperproliferating cells comprising combined administration of a cannabinoid receptor agonist and radiation therapy
 
Abstract
Disclosed is a method for treating a condition associated with hyperproliferating cells, the method including the steps of administering to a subject having the condition a composition including at least one cannabinoid receptor agonist, optionally administering to the subject a photodynamic compound, and administering radiation to the subject in whom the at least one cannabinoid receptor agonist is present so as to treat the condition.

US20190290657A1

United States


Inventor: 
Roger Dumoulin-White
Arkady Mandel
Current Assignee:
Theralase Technologies Inc

Worldwide applications
2019  CA   US

Application US16/365,148 events
2018-03-26 Priority to US201862648334P
2019-03-26 Application filed by Theralase Technologies Inc
2019-03-26 Priority to US16/365,148
2019-03-26 Assigned to THERALASE TECHNOLOGIES, INC.
2019-09-26 Publication of US20190290657A1
2019-11-28 Application status is Pending

Bullboard Posts